



PRESS RELEASE: Paris November 6, 2019: Bio-Modeling Systems updates its pipeline of therapies, diagnostics, and bioprocesses and invites you to meet its team at BioFit and Polepharma Bio-Production conferences.

BMSystems Group addresses two complementary targets in *Pharma*, *Biotech*, *Cosmetics*, *BioProduction* businesses:

- **For R&D, Translational Medicine & Digital Health Executives**, we offer *robust alternative decision-making to de-risk, save time and costs* of R&D and Digital Health programs,
- **For Business Developers, Patients Groups & Investors**, we discover *novel low-risk, highly effective and cost-effective* diagnostic, therapy, nutrition, cosmetic, bioprocess solutions for spin-offs or out-licensing.

Created in 2004, profitable since 2006, thanks to our recurrent clients, CADI™ Discovery already generated robust heuristic models *describing the complex mechanisms of the diseases* that led to therapeutics, diagnostics and bio-production programs at various stages ready for development:

- **COMBO-THERAPIES:**
 1. CADI-T1011: Multi-Resistance Infectious Diseases,
 2. CADI-T1031: CFS/ME (Chronic Fatigue Syndrome) Low-Grade Chronic Inflammation,
 3. CADI-T1032: Gulf War Syndrome,
 4. CADI-T2011: Attenuation of the Core Symptoms of Autism,
 5. *CADI-T3021: Parkinson's Disease,*
 6. *CADI-T4021: Metabolic Syndrome,*
 7. CADI-T4031: Attenuation of Developmental Consequences of Children Malnutrition.
- **COMBO-DIAGNOSTICS:**
 1. *CADI-D3041: Alzheimer's Disease Early Diagnostics.*
- **CADI™ BIO-PRODUCTION:**
 1. CADI-B8011: Program Synthons (16 molecules study),
 2. *CADI-B8021: Full Human Protein Glycosylation in Yeast.*
- **LATEST NOVEL CADI R&D PROGRAM:**
 - *CADI-R901: Cardiovascular Diseases domain: Atherosclerosis mechanisms*

For all programs details, we warmly invite you to download *our Short corporate Presentation* (slides 10, 11, 12) to discover all our achievements in diagnostics, therapeutics, cosmetics, digital-Health and bio-production.

Do not hesitate to meet us during the *international event BioFit* (December 10-11, 2019 / Marseille, FR) or during the *PolePharma Bio-Production Conference* (December 12-13, 2019 /Tours, FR)

Read our publication in *Current Opinion in Pharmacology* describing why and how we invented CADI™ Discovery

Manuel GEA
CEO Bio-Modeling Systems
***CADI: Computer Augmented Deductive Integration**

About Bio-Modeling Systems

Bio-Modeling Systems is the world's first Mechanisms-Based Medicine company that successfully changed the discovery paradigm, addressing the complexity of life sciences mechanisms and the digital "garbage in garbage out" reality through CADI*™ Discovery based on Augmented Intelligence, the other complementary AI, for complex systems.

Created in 2004, profitable since 2006, thanks to our recurrent clients, CADI™ Discovery already delivered operational outputs:

A world's first in CNS diseases with CEA: 2 awards (US & Europe), Pherecydes-Pharma: First BMSystems' therapeutic spin-off, against MR infections diseases, Compassionate Use success, CEA/BMSystems collaborative research success in CNS that led to the co-owned therapeutic class patent with a worldwide exclusive license to a CEA's spin-off, 14 R&D validated successes, 8 novel combo-therapies and combo-diagnostics ready for development, Mechanisms-Based Cosmetics developed to address Cosmetics business, GEMMA (Autism & Microbiota) H2020 program with €14.2M funding. BMSystems is the Integrative Biology Partner.